Viral load rebound, symptom rebound common with VV116, nirmatrelvir-ritonavir in mild-to-moderate COVID-19.

No evidence seen for increased risk for stroke in one- to 21-day or 22- to 42-day windows compared with 43- to 90-day window after vaccine

Reduced risk seen for venous thromboembolism, arterial thrombosis/thromboembolism, and heart failure.

As of March 9, 2024, only FDA-approved Paxlovid (manufactured and labeled in accordance with the New Drug Application) may be dispensed.

The decision reflects the reality that COVID-19 cases are falling as the respiratory virus season winds down.

New research suggests that US cancer survivors are more likely than the general population to develop moderate to severe COVID-19 and long COVID.

In some individuals, there were many viral amino acid substitutions, indicating strong positive selection.

VE against COVID-19-associated ED, urgent care encounters was 51 percent during first 7 to 59 days after updated dose.

This is the first time the agency has loosened its COVID-19 isolation guidelines since 2021.

Second booster appropriate as long as at least four months have passed since last COVID-19 shot